^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

Published date:
10/05/2021
Excerpt:
Ganitumab was tested in combination with metformin and paclitaxel (PGM)...In the HR-negative/HER2-negative subtype, pCR rates were higher in the arm compared to control…
Secondary therapy:
paclitaxel + metformin
DOI:
https://doi.org/10.1038/s41523-021-00337-2